Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

K. John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva‐Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C. Benson; Margaret V. Ragni

doi:10.1111/jth.15270

journal article Open Access Jun 01, 2021

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

K. John Pasi

Toshko Lissitchkov Vasily Mamonov Tim Mant Margarita Timofeeva Catherine Bagot Pratima Chowdary

Pencho Georgiev Liana Gercheva‐Kyuchukova Kate Madigan Huy Van Nguyen Qifeng Yu Baisong Mei Craig C. Benson Margaret V. Ragni

Journal of Thrombosis and Haemostasis Vol. 19 No. 6 pp. 1436-1446 · Elsevier BV

View at Publisher Save 10.1111/jth.15270

Topics

No keywords indexed for this article. Browse by subject →

References

54

[1]

Monroe "What does it take to make the perfect clot?" Arterioscler Thromb Vasc Biol (2006) 10.1161/01.atv.0000193624.28251.83

[2]

Bolton‐Maggs "Haemophilias A and B" Lancet (2003) 10.1016/s0140-6736(03)13405-8

[3]

Peyvandi "The past and future of haemophilia: diagnosis, treatments, and its complications" Lancet (2016) 10.1016/s0140-6736(15)01123-x

[4]

Pipe "Optimizing outcomes for patients with severe haemophilia a" Haemophilia (2007) 10.1111/j.1365-2516.2007.01552.x

[5]

Ljung "The current status of prophylactic replacement therapy in children and adults with haemophilia" Br J Haematol (2015) 10.1111/bjh.13365

[6]

Srivastava "Guidelines for the management of hemophilia" Haemophilia (2013) 10.1111/j.1365-2516.2012.02909.x

[7]

Bauer "Current challenges in the management of hemophilia" Am J Manag Care (2015)

[8]

Mannucci "Present and future challenges in the treatment of haemophilia: a clinician's perspective" Blood Transfus (2013)

[9]

World Federation of Hemophilia. Treatment safety and supply. 2020. Available from: https://www.wfh.org/en/our‐work‐treatment/treatment‐safety‐supply. Last accessed 4 Mar 2020.

[10]

Morfini "European study on orthopaedic status of haemophilia patients with inhibitors" Haemophilia (2007) 10.1111/j.1365-2516.2007.01518.x

[11]

Oladapo "Inhibitor clinical burden of disease: a comparative analysis of the CHESS data" Orphanet J Rare Dis (2018) 10.1186/s13023-018-0929-9

[12]

Benson "Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice" Eur J Haematol (2012) 10.1111/j.1600-0609.2012.01754.x

[13]

Collins "Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (4th edition)" Br J Haematol (2013) 10.1111/bjh.12091

[14]

Kempton "Toward optimal therapy for inhibitors in hemophilia" Blood (2014) 10.1182/blood-2014-05-577643

[15]

Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

J. ASTERMARK, A. ROCINO, M. VON DEPKA et al.

Haemophilia 2007 10.1111/j.1365-2516.2006.01403.x

[16]

Eichinger "Thrombin generation in haemophilia a patients with factor VIII inhibitors after infusion of recombinant factor VIIIa" Eur J Clin Invest (2009) 10.1111/j.1365-2362.2009.02168.x

[17]

Goodeve "Hemophilia B: molecular pathogenesis and mutation analysis" J Thromb Haemost (2015) 10.1111/jth.12958

[18]

Mauro "Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report" Blood Transfus (2016)

[19]

Chowdary "Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial" J Thromb Haemost (2015) 10.1111/jth.12864

[20]

Hartmann "2017 Clinical trials update: innovations in hemophilia therapy" Am J Hematol (2016) 10.1002/ajh.24543

[21]

Waters "Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor" Blood (2011) 10.1182/blood-2010-10-311936

[22]

Gissel "Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia" Thromb Res (2012) 10.1016/j.thromres.2012.08.299

[23]

Polderdijk "Design and characterization of an APC‐specific serpin for the treatment of hemophilia" Blood (2017) 10.1182/blood-2016-05-718635

[24]

Sehgal "An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia" Nat Med (2015) 10.1038/nm.3847

[25]

Shima "Factor VIII‐mimetic function of humanized bispecific antibody in hemophilia A" N Engl J Med (2016) 10.1056/nejmoa1511769

[26]

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg, Johnny N. Mahlangu, Benjamin Kim et al.

New England Journal of Medicine 2017 10.1056/nejmoa1703068

[27]

Mahlangu "Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A" Blood (2014) 10.1182/blood-2013-10-529974

[28]

Pasi "Targeting of antithrombin in hemophilia A or B with RNAi therapy" N Engl J Med (2017) 10.1056/nejmoa1616569

[29]

Lenting "Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?" Blood (2017) 10.1182/blood-2017-08-801662

[30]

Walker "Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies" Br J Anaesth (2002) 10.1093/bja/88.6.848

[31]

Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate

Andrew S. Levey, Josef Coresh, Tom Greene et al.

Annals of Internal Medicine 2006 10.7326/0003-4819-145-4-200608150-00004

[32]

EuroQol - a new facility for the measurement of health-related quality of life

Health Policy 1990 10.1016/0168-8510(90)90421-9

[33]

von Mackensen "Validation of the haemophilia‐specific quality of life questionnaire for adult patients with haemophilia (HAEM‐A‐QOL)" Haematologica (2005)

[34]

Katarey "Drug‐induced liver injury" Clin Med (Lond) (2016) 10.7861/clinmedicine.16-6-s104

[35]

Wyrwich "Interpreting important health‐related quality of life change using the Haem‐a‐QoL" Haemophilia (2015) 10.1111/hae.12642

[36]

Sokol "Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the mega follow‐up study" J Thromb Haemost (2018) 10.1111/jth.13960

[37]

de la Morena‐Barrio "Incidence and features of thrombosis in children with inherited antithrombin deficiency" Haematologica (2019) 10.3324/haematol.2018.210666

[38]

Escuriola Ettingshausen "Symptomatic onset of severe hemophilia a in childhood is dependent on the presence of prothrombotic risk factors" Thromb Haemost (2001) 10.1055/s-0037-1615679

[39]

Shetty "Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients" Br J Haematol (2007) 10.1111/j.1365-2141.2007.06693.x

[40]

Riley "Widely used types and clinical applications of D‐dimer assay" Lab Med (2016) 10.1093/labmed/lmw001

[41]

Butenas ""Normal" thrombin generation" Blood (1999) 10.1182/blood.v94.7.2169.419k22_2169_2178

[42]

Machlus "Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram" Thromb Haemost (2009) 10.1160/th09-03-0180

[43]

FDA. Feiba US prescribing information. Available from: https://www.fda.gov/media/78852/download. Last accessed 4 Mar 2020.

[44]

Qian K, Huang S, Akinc A, Liu J. Thrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia. WFH 2018 World Congress. 2018;M‐P‐219 (141).

[45]

Nordisk N. US prescribing information: Novoseven®, coagulation factor VIIa (recombinant), for intravenous use only. 2006. Available from: https://www.fda.gov/media/70435/download. Last accessed 27 August 2020.

[46]

Sanofi. An open‐label extension study of an investigational drug, fitusiran, in patients with moderate or severe hemophilia a or b. ClinicalTrials.gov NCT02554773, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02554773. Last accessed 27 August 2020.

[47]

Sanofi. A study of fitusiran (ALN‐AT3SC) in severe hemophilia a and b patients with inhibitors (ATLAS‐INH). ClinicalTrials.gov NCT03417102, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03417102. Last accessed 27 August 2020.

[48]

Sanofi. A study of fitusiran (ALN‐AT3SC) in severe hemophilia a and b patients without inhibitors. ClinicalTrials.gov NCT03417245, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03417245. Last accessed 27 August 2020.

[49]

Sanofi. A study of fitusiran in severe hemophilia a and b patients previously receiving factor or bypassing agent prophylaxis (ATLAS‐PPX). ClinicalTrials.gov NCT03549871, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03549871. Last accessed 27 August 2020.

[50]

Sanofi. Fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia a or b (ATLAS‐PEDS). ClinicalTrials.gov NCT03974113, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03974113. Last accessed 27 August 2020.

Showing 50 of 54 references

Cited By

90

Hepatocyte targeting via the asialoglycoprotein receptor

Fabricio Ramírez-Cortés, Petra Ménová · 2025

RSC Medicinal Chemistry

A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy

Jiaying Zhang, Bo Chen · 2023

International Journal of Nanomedici...

Metrics

90

Citations

54

References

Details

Published: Jun 01, 2021
Vol/Issue: 19(6)
Pages: 1436-1446
License: View

Authors

K

K. John Pasi

From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy’s and St. Thomas’ NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) — all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private...

T

Toshko Lissitchkov

Department of Chemotherapy Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Specialized Hospital for Active Treatment of Hematological Diseases Sofia Bulgaria

Liana Gercheva‐Kyuchukova

Multiprofile Hospital for Active Treatment “Sveta Marina”, Clinical Hematology Clinic Varna Bulgaria

Division of Hematology/Oncology Department of Medicine University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA

Funding

Alnylam Pharmaceuticals

Sanofi Genzyme

Cite This Article

K. John Pasi, Toshko Lissitchkov, Vasily Mamonov, et al. (2021). Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort. Journal of Thrombosis and Haemostasis, 19(6), 1436-1446. https://doi.org/10.1111/jth.15270

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

You May Also Like